* Fulcrum Therapeutics Inc FULC.OQ reported a quarterly
adjusted
loss of 40 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -50 cents. The mean expectation of
seven analysts for the quarter was for a loss of 43 cents per
share. Wall Street expected results to range from -50 cents
to -38 cents per share.
* Revenue rose 27.2% to $871.00 thousand from a year ago;
analysts
expected $461.17 thousand.
* Fulcrum Therapeutics Inc's reported EPS for the quarter
was a
loss of 40 cents.
* The company reported a quarterly loss of $24.76 million.
* Fulcrum Therapeutics Inc shares had risen by 44.1% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $11.00
This summary was machine generated from LSEG data February 27 at
02:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.43 -0.40 Beat
Sep. 30 2023 -0.43 -0.39 Beat
Jun. 30 2023 -0.44 -0.38 Beat
Mar. 31 2023 -0.46 -0.41 Beat